Published in Adv Hematol on June 26, 2011
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A (2012) 3.22
Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood (2012) 1.97
IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep (2013) 1.32
Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev (2012) 1.26
Recent advances in acute myeloid leukemia stem cell biology. Haematologica (2012) 1.25
Myeloid malignancies: mutations, models and management. BMC Cancer (2012) 1.24
Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest (2014) 1.20
CR Cistrome: a ChIP-Seq database for chromatin regulators and histone modification linkages in human and mouse. Nucleic Acids Res (2013) 0.95
The epigenetic landscape of acute myeloid leukemia. Adv Hematol (2014) 0.94
Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des (2013) 0.91
Digging deep into "dirty" drugs - modulation of the methylation machinery. Drug Metab Rev (2015) 0.83
DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells. Oncotarget (2013) 0.82
Genomic tools in acute myeloid leukemia: From the bench to the bedside. Cancer (2014) 0.79
Glial progenitors as targets for transformation in glioma. Adv Cancer Res (2014) 0.78
The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells. Sci Rep (2015) 0.78
Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget (2016) 0.77
Life after transplant: are we becoming high maintenance in AML? Bone Marrow Transplant (2016) 0.75
Fingerprinting acute leukemia: DNA methylation profiling of B-acute lymphoblastic leukemia. Cancer Discov (2012) 0.75
Mutation analysis of JAK2V617F, FLT3-ITD, NPM1, and DNMT3A in Chinese patients with myeloproliferative neoplasms. Biomed Res Int (2014) 0.75
Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. Front Pharmacol (2017) 0.75
Targeting apoptosis in acute myeloid leukaemia. Br J Cancer (2017) 0.75
Molecular characterization of EZH2-mutant patients with myelodysplastic/myeloproliferative neoplasms. Leukemia (2017) 0.75
Brain Tumor-Related Epilepsy: a Current Review of the Etiologic Basis and Diagnostic and Treatment Approaches. Curr Neurol Neurosci Rep (2017) 0.75
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science (2009) 32.97
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature (2010) 18.63
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
DNMT3A mutations in acute myeloid leukemia. N Engl J Med (2010) 14.07
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med (2008) 13.02
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell (2011) 9.16
Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature (2010) 8.87
UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature (2007) 8.32
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet (2011) 6.98
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol (2009) 6.43
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med (2010) 5.68
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2010) 5.62
JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell (2006) 5.54
The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature (2006) 5.51
Human PAD4 regulates histone arginine methylation levels via demethylimination. Science (2004) 5.46
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol (2009) 5.06
CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol (2004) 5.01
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood (2009) 4.64
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia (2009) 4.53
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia (2011) 4.28
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
New insights to the MLL recombinome of acute leukemias. Leukemia (2009) 4.07
Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood (2005) 3.90
Array-based genomic resequencing of human leukemia. Oncogene (2010) 3.77
JMJD6 is a histone arginine demethylase. Science (2007) 3.48
TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol (2011) 3.01
Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst (2010) 3.00
Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res (2007) 2.95
NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol (2007) 2.85
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood (2002) 2.71
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res (2010) 2.69
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res (2006) 2.69
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia (2010) 2.65
D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats. Eur J Neurosci (2003) 2.62
Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res (2005) 2.57
NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d-2-hydroxyglutaric aciduria. Eur J Neurosci (2002) 2.54
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood (2011) 2.47
Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood (2010) 2.40
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst (2003) 2.22
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood (2009) 2.18
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood (2010) 2.15
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia (2011) 2.12
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
Demethylation of trimethylated histone H3 Lys4 in vivo by JARID1 JmjC proteins. Nat Struct Mol Biol (2007) 1.97
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica (2009) 1.95
Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol (2010) 1.90
Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia (2011) 1.88
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia (2011) 1.79
Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. Blood (1996) 1.77
Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol (2002) 1.61
The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood (2010) 1.60
DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica (2002) 1.60
Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci (2009) 1.48
Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood (1998) 1.36
Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol (2008) 1.34
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 1.32
The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia (2010) 1.25
DOT1L regulates dystrophin expression and is critical for cardiac function. Genes Dev (2011) 1.25
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood (2010) 1.22
Gene silencing by DNA methylation in haematological malignancies. Br J Haematol (2007) 1.20
IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell (2010) 1.15
Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer (2010) 1.13
N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorg Med Chem Lett (2008) 1.11
IDH1 and IDH2: not your typical oncogenes. Cancer Cell (2010) 1.00
Phase II trial of DNA methyltransferase 1 inhibition with the antisense oligonucleotide MG98 in patients with metastatic renal carcinoma: a National Cancer Institute of Canada Clinical Trials Group investigational new drug study. Invest New Drugs (2006) 0.99
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol (2003) 0.97
Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem (2009) 0.96
IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia (2010) 0.96
A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin Cancer Res (2008) 0.95
Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematol Oncol (2010) 0.91
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs (2003) 0.89
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet (2012) 3.33
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol (2012) 3.20
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2012) 2.92
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09
Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion (2006) 1.96
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nat Med (2013) 1.89
TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell (2011) 1.87
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A (2010) 1.81
The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem (2012) 1.79
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med (2013) 1.71
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. Blood (2010) 1.42
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood (2013) 1.41
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood (2013) 1.33
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med (2015) 1.15
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood (2013) 1.14
Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. J Clin Invest (2013) 1.12
Detection of an NRAS mutation in Erdheim-Chester disease. Blood (2013) 1.10
Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell (2013) 1.08
Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood (2011) 1.02
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica (2012) 0.99
Epigenetic alterations in hematopoietic malignancies. Int J Hematol (2012) 0.98
D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev (2014) 0.97
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem (2011) 0.97
GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood (2013) 0.96
Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. J Clin Invest (2015) 0.96
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood (2012) 0.96
HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med (2013) 0.94
Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. Blood (2010) 0.92
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica (2010) 0.91
Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. J Surg Res (2005) 0.89
Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms. Am J Hematol (2010) 0.88
Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations. Haematologica (2014) 0.88
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels. Leuk Lymphoma (2012) 0.88
Importance of genetics in the clinical management of chronic myelomonocytic leukemia. J Clin Oncol (2013) 0.87
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res (2012) 0.86
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
Recent discoveries in molecular characterization of acute myeloid leukemia. Curr Hematol Malig Rep (2014) 0.81
Molecular alterations underlying eosinophilic and mast cell malignancies. Discov Med (2011) 0.80
Modulation of resistance to regional chemotherapy in the extremity melanoma model. Surgery (2004) 0.80
Immunotherapy of surgical malignancies. Curr Probl Surg (2004) 0.79
Focus on the epigenome in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program (2013) 0.78
An 87-year-old woman with respiratory distress and alveolar hemorrhage after transfusion. Chest (2006) 0.78
In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J Am Coll Surg (2004) 0.78
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. Haematologica (2014) 0.77
The importance of subclonal genetic events in MDS. Blood (2013) 0.77
Hairy cell leukemia: update and current therapeutic approach. Curr Opin Hematol (2015) 0.76
Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med (2016) 0.76
BRAF-mutant hematopoietic malignancies. Oncotarget (2014) 0.76
Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma (2014) 0.76
FISHing for TET2: Utility of FISH for TET2 deletions detection in clinical samples. Leuk Res (2011) 0.75
Refining the prognostic importance of the diversity of FLT3 internal tandem duplications. Leuk Lymphoma (2012) 0.75
The mutational landscape of paroxysmal nocturnal hemoglobinuria revealed: new insights into clonal dominance. J Clin Invest (2014) 0.75
Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms. Curr Hematol Malig Rep (2012) 0.75
Histiocytic neoplasms in the era of personalized genomic medicine. Curr Opin Hematol (2016) 0.75
Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia. Acta Haematol (2012) 0.75